\-\ Texto\\:\\ \ \(0\)\
\-\ na\\,\\ k\\,\\ cl\\,\\ co2\\,\\ glucose\\,\\ bun\\,\\ creatinine\\,\\ ca\\,\\ drawn\\ on\\ the\\ same\\ day\\ the\\ ct\\ scan\\ was\\ taken\\ were\\ all\\ normal\\.\ \(0\)\
\-\ pt\\ is\\ currently\\ not\\ receiving\\ treatment\\ but\\ is\\ being\\ worked\\ up\\ followed\\ with\\ serial\\ ct\\ scans\\ due\\ to\\ unexplained\\ weight\\ loss\\.\ \(0\)\
\-\ 1\\.\\ the\\ parenchyma\\ of\\ the\\ lung\\ demonstrates\\ bilateral\\ upper\\ lobe\\ predominant\\ fibrotic\\ changes\\ with\\ interlobular\\ septal\\ thickening\\.\\ 2\\.\\ \\ numerous\\ 1\\ cm\\ nodular\\ densities\\ with\\ in\\ the\\ periphery\\.\ \(0\)\
\-\ 3\\.\\ \\ as\\ well\\ as\\ dominant\\ fibrotic\\ masses\\ at\\ the\\ end\\ of\\ the\\ bronchovascular\\ bundle\\ on\\ the\\ right\\ side\\ seen\\ best\\ on\\ image\\ \\#16\\ measuring\\ 3\\.6\\ cm\\ x\\ 1\\.7\\ cm\\ and\\ on\\ the\\ left\\ upper\\ lobe\\ seen\\ best\\ on\\ image\\ \\#10\\ measuring\\ 2\\.4\\ cm\\ x\\ 1\\.8\\ cm\\ with\\ associated\\ traction\\ bronchiectasis\\,\\ as\\ well\\ as\\ some\\ sparse\\ areas\\ of\\ effected\\ regions\\ within\\ the\\ superior\\ segments\\ of\\ the\\ lower\\ lobes\\ bilaterally\\ as\\ well\\ as\\ the\\ right\\ middle\\ lobe\\,\\ which\\ appears\\ to\\ have\\ not\\ changed\\ significantly\\ in\\ comparison\\ with\\ the\\ prior\\ ct\\ scan\\ performed\\ on\\ 27\\ feb\\ 2002\\.\ \(0\)\
\-\ 4\\.\\ \\ no\\ evidence\\ of\\ pleural\\ effusion\\ or\\ pneumothorax\\.\ \(0\)\
\-\ 5\\.\\ \\ mediastinum\\ demonstrates\\ no\\ evidence\\ of\\ lymphadenopathy\\ pathologic\\ by\\ size\\ criteria\\.\\ \\ \ \(0\)\
\-\ 6\\.\\ \\ no\\ evidence\\ of\\ axillary\\ lymphadenopathy\\ pathologic\\ by\\ size\\ criteria\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ nodular\\ interstitial\\ pattern\\:\\ granulomatous\\ diseases\\ both\\ infectious\\ \\(tb\\,\\ fungal\\,\\ bacteria\\,\\ atypical\\ mycobacterium\\)\\ and\\ non\\-\\ infectious\\ \\(sarcoidosis\\,\\ vasculitis\\-granulomatosis\\ diseases\\,\\ histiocytosis\\)\\ hematogenous\\ spread\\ of\\ malignancy\\,\\ and\\,\\ pneumoconiosis\\.\ \(0\)\
\-\ history\\ \\(can\\ include\\ gestational\\ age\\,\\ or\\ age\\ in\\ days\\,\\ weeks\\,\\ months\\)\\:\ \(0\)\
\-\ 70\\ y\\/o\\ female\\ for\\ follow\\ up\\ ct\\ scan\\ to\\ monitor\\ for\\ any\\ pulmonary\\ changes\\ due\\ to\\ a\\ recent\\ 15lb\\ weight\\ loss\\,\\ otherwise\\ asymptomatic\\.\ \(0\)\
\-\ sarcoidosis\\ is\\ a\\ granulomatous\\ disorder\\ of\\ unknown\\ etiology\\ that\\ can\\ affect\\ multiple\\ systems\\;\\ the\\ presence\\ of\\ noncaseating\\ granulomas\\ in\\ the\\ involved\\ organs\\ is\\ what\\ characterizes\\ it\\ pathologically\\.\\ \\ sarcoidosis\\ is\\ estimated\\ to\\ have\\ a\\ prevalence\\ of\\ 10\\-20\\ per\\ 100\\,000\\ and\\ is\\ 3\\-4\\ times\\ more\\ common\\ in\\ african\\ americans\\ than\\ caucasians\\.\\ \\ the\\ most\\ common\\ target\\ of\\ sarcoidosis\\ is\\ the\\ lungs\\,\\ around\\ 90\\%\\ of\\ all\\ patients\\ with\\ sarcoidosis\\ have\\ lung\\ involvement\\,\\ resulting\\ in\\ the\\ main\\ symptoms\\ including\\ cough\\,\\ dyspnea\\,\\ chest\\ pain\\,\\ and\\ the\\ less\\ common\\ features\\ include\\ fatigue\\,\\ weakness\\,\\ malaise\\,\\ fever\\,\\ and\\ weight\\ loss\\.\\ \\ sarcoidosis\\,\\ when\\ in\\ its\\ extrapulmonary\\ form\\,\\ can\\ result\\ in\\ a\\ plethora\\ of\\ other\\ complaints\\ depending\\ on\\ the\\ organ\\ system\\ affected\\.\\ \\ but\\ approximately\\ 50\\%\\ of\\ those\\ with\\ sarcoidosis\\ are\\ asymptomatic\\ at\\ the\\ time\\ it\\ is\\ discovered\\.\\ \\ the\\ treatment\\ for\\ sarcoidosis\\ is\\ not\\ straightforward\\.\\ \\ it\\ is\\ typically\\ agreed\\ upon\\ that\\ treatment\\ should\\ begin\\ if\\ the\\ patient\\ is\\ symptomatic\\,\\ if\\ lung\\ function\\ is\\ deteriorating\\,\\ or\\ the\\ radiological\\ findings\\ associated\\ with\\ sarcoidosis\\ are\\ worsening\\.\\ \\ the\\ current\\ primary\\ treatment\\ is\\ with\\ daily\\ oral\\ corticosteroids\\.\\ \\ the\\ best\\ dose\\ is\\ not\\ known\\ so\\ a\\ dose\\ must\\ be\\ chosen\\ by\\ balancing\\ the\\ risk\\ of\\ adverse\\ effects\\ versus\\ the\\ benefits\\ of\\ therapy\\.\\ \\ treatment\\ typically\\ lasts\\ between\\ 6\\ to\\ 12\\ months\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.4077721304427192\ \(0\)\
\-\ the\\:\\ 0\\.2689504199970912\ \(0\)\
\-\ is\\:\\ 0\\.18456271836874502\ \(0\)\
\-\ of\\:\\ 0\\.16014830525833576\ \(0\)\
\-\ cm\\:\\ 0\\.1382323915059644\ \(0\)\
\-\ fibrotic\\:\\ 0\\.11887148926210024\ \(0\)\
\-\ best\\:\\ 0\\.1162014610688894\ \(0\)\
\-\ as\\:\\ 0\\.11603362851184974\ \(0\)\
\-\ treatment\\:\\ 0\\.11465457480754297\ \(0\)\
\-\ on\\:\\ 0\\.10177054237011246\ \(0\)\
\-\ weight\\:\\ 0\\.1007080741944888\ \(0\)\
\-\ in\\:\\ 0\\.09580234323772086\ \(0\)\
\-\ criteria\\:\\ 0\\.09547392460941675\ \(0\)\
\-\ dose\\:\\ 0\\.08990842275517713\ \(0\)\
\-\ diseases\\:\\ 0\\.08845567485389254\ \(0\)\
\-\ loss\\:\\ 0\\.08798318888419036\ \(0\)\
\-\ lung\\:\\ 0\\.08784959140862268\ \(0\)\
\-\ scan\\:\\ 0\\.08568008704467348\ \(0\)\
\-\ granulomatous\\:\\ 0\\.08558272054433091\ \(0\)\
\-\ with\\:\\ 0\\.08483505555841751\ \(0\)\
\-\ lobe\\:\\ 0\\.08345687376267574\ \(0\)\
\-\ evidence\\:\\ 0\\.08197042945231457\ \(0\)\
\-\ common\\:\\ 0\\.08190010534356813\ \(0\)\
\-\ pathologic\\:\\ 0\\.07888677666691041\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.07783456332090744\ \(0\)\
\-\ infectious\\:\\ 0\\.07746764071259295\ \(0\)\
\-\ 15lb\\:\\ 0\\.07698391812056272\ \(0\)\
\-\ plethora\\:\\ 0\\.07698391812056272\ \(0\)\
\-\ nodular\\:\\ 0\\.07667011714232946\ \(0\)\
\-\ not\\:\\ 0\\.07601571595056635\ \(0\)\
\-\ can\\:\\ 0\\.07578465648041124\ \(0\)\
\-\ measuring\\:\\ 0\\.07448144398605293\ \(0\)\
\-\ it\\:\\ 0\\.07392425373397056\ \(0\)\
\-\ effected\\:\\ 0\\.07356224363805808\ \(0\)\
\-\ characterizes\\:\\ 0\\.07356224363805808\ \(0\)\
\-\ caucasians\\:\\ 0\\.07356224363805808\ \(0\)\
\-\ extrapulmonary\\:\\ 0\\.07356224363805808\ \(0\)\
\-\ balancing\\:\\ 0\\.07356224363805808\ \(0\)\
\-\ ct\\:\\ 0\\.07330709359647462\ \(0\)\
\-\ to\\:\\ 0\\.07220716092481641\ \(0\)\
\-\ have\\:\\ 0\\.07214344196211567\ \(0\)\
\-\ deteriorating\\:\\ 0\\.07113452695739186\ \(0\)\
\-\ well\\:\\ 0\\.06992667597134265\ \(0\)\
\-\ sparse\\:\\ 0\\.06925144360398129\ \(0\)\
\-\ noncaseating\\:\\ 0\\.06925144360398129\ \(0\)\
\-\ straightforward\\:\\ 0\\.06925144360398129\ \(0\)\
\-\ typically\\:\\ 0\\.06758748696139635\ \(0\)\
\-\ bundle\\:\\ 0\\.0664119922107656\ \(0\)\
\-\ agreed\\:\\ 0\\.0664119922107656\ \(0\)\
\-\ lasts\\:\\ 0\\.0664119922107656\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.06554351758568266\ \(0\)\
\-\ size\\:\\ 0\\.06518911558272475\ \(0\)\
\-\ unexplained\\:\\ 0\\.06429117799238253\ \(0\)\
\-\ americans\\:\\ 0\\.06429117799238253\ \(0\)\
\-\ bronchovascular\\:\\ 0\\.06186346131171633\ \(0\)\
\-\ mycobacterium\\:\\ 0\\.06186346131171633\ \(0\)\
\-\ image\\:\\ 0\\.06157266140422974\ \(0\)\
\-\ by\\:\\ 0\\.06132717857200693\ \(0\)\
\-\ chosen\\:\\ 0\\.060562601047594734\ \(0\)\
\-\ age\\:\\ 0\\.06044363554347168\ \(0\)\
\-\ interlobular\\:\\ 0\\.059980377958305756\ \(0\)\
\-\ adverse\\:\\ 0\\.059980377958305756\ \(0\)\
\-\ and\\:\\ 0\\.05968337204867778\ \(0\)\
\-\ changes\\:\\ 0\\.058185786507630066\ \(0\)\
\-\ worked\\:\\ 0\\.05755266127763955\ \(0\)\
\-\ pneumoconiosis\\:\\ 0\\.05755266127763955\ \(0\)\
\-\ all\\:\\ 0\\.057311387085549594\ \(0\)\
\-\ include\\:\\ 0\\.057283921212528684\ \(0\)\
\-\ 10\\:\\ 0\\.05629788286297521\ \(0\)\
\-\ months\\:\\ 0\\.05604098634703779\ \(0\)\
\-\ pathologically\\:\\ 0\\.05601407014854545\ \(0\)\
\-\ if\\:\\ 0\\.05593931269470185\ \(0\)\
\-\ begin\\:\\ 0\\.055669577924228976\ \(0\)\
\-\ benefits\\:\\ 0\\.055669577924228976\ \(0\)\
\-\ due\\:\\ 0\\.0553418069266381\ \(0\)\
\-\ feb\\:\\ 0\\.055338598733421715\ \(0\)\
\-\ hematogenous\\:\\ 0\\.05471320988442386\ \(0\)\
\-\ predominant\\:\\ 0\\.05413098679513488\ \(0\)\
\-\ granulomas\\:\\ 0\\.05413098679513488\ \(0\)\
\-\ changed\\:\\ 0\\.053854277165142884\ \(0\)\
\-\ co2\\:\\ 0\\.053586353467879246\ \(0\)\
\-\ cl\\:\\ 0\\.05332667489840716\ \(0\)\
\-\ bacteria\\:\\ 0\\.05332667489840716\ \(0\)\
\-\ malaise\\:\\ 0\\.05332667489840716\ \(0\)\
\-\ drawn\\:\\ 0\\.05259239566604079\ \(0\)\
\-\ prevalence\\:\\ 0\\.05259239566604079\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.05213612846163541\ \(0\)\
\-\ upper\\:\\ 0\\.05144892228225776\ \(0\)\
\-\ traction\\:\\ 0\\.05089895821774095\ \(0\)\
\-\ associated\\:\\ 0\\.05074518351444984\ \(0\)\
\-\ bronchiectasis\\:\\ 0\\.05034234633968299\ \(0\)\
\-\ or\\:\\ 0\\.05023956581749914\ \(0\)\
\-\ receiving\\:\\ 0\\.049990675137797605\ \(0\)\
\-\ estimated\\:\\ 0\\.049990675137797605\ \(0\)\
\-\ radiological\\:\\ 0\\.049990675137797605\ \(0\)\
\-\ effects\\:\\ 0\\.049990675137797605\ \(0\)\
\-\ affect\\:\\ 0\\.04982018676105811\ \(0\)\
\-\ target\\:\\ 0\\.04982018676105811\ \(0\)\
\-\ organs\\:\\ 0\\.04965307461465903\ \(0\)\
\-\ organ\\:\\ 0\\.04948920757025085\ \(0\)\
\-\ monitor\\:\\ 0\\.049170721183536124\ \(0\)\
\-\ creatinine\\:\\ 0\\.04901587486433038\ \(0\)\
\-\ segments\\:\\ 0\\.04886381872125299\ \(0\)\
\-\ periphery\\:\\ 0\\.048567687016811474\ \(0\)\
\-\ demonstrates\\:\\ 0\\.0483685033234658\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.048281595631964005\ \(0\)\
\-\ densities\\:\\ 0\\.04814210671030572\ \(0\)\
\-\ up\\:\\ 0\\.0476245897214973\ \(0\)\
\-\ but\\:\\ 0\\.04760911262252493\ \(0\)\
\-\ axillary\\:\\ 0\\.04735038077806356\ \(0\)\
\-\ no\\:\\ 0\\.046962263206362286\ \(0\)\
\-\ septal\\:\\ 0\\.0468610328271674\ \(0\)\
\-\ gestational\\:\\ 0\\.04674300450286992\ \(0\)\
\-\ fatigue\\:\\ 0\\.046626604207442794\ \(0\)\
\-\ glucose\\:\\ 0\\.046511787638702\ \(0\)\
\-\ systems\\:\\ 0\\.046511787638702\ \(0\)\
\-\ bun\\:\\ 0\\.04639851227855344\ \(0\)\
\-\ what\\:\\ 0\\.04628673729846454\ \(0\)\
\-\ 2002\\:\\ 0\\.046067533087746186\ \(0\)\
\-\ comparison\\:\\ 0\\.045853878951297805\ \(0\)\
\-\ depending\\:\\ 0\\.045853878951297805\ \(0\)\
\-\ na\\:\\ 0\\.04564550076852133\ \(0\)\
\-\ daily\\:\\ 0\\.04564550076852133\ \(0\)\
\-\ seen\\:\\ 0\\.04532641842707455\ \(0\)\
\-\ significantly\\:\\ 0\\.045243573015382725\ \(0\)\
\-\ dominant\\:\\ 0\\.045049567054570076\ \(0\)\
\-\ serial\\:\\ 0\\.04431528782220372\ \(0\)\
\-\ discovered\\:\\ 0\\.04388682587400243\ \(0\)\
\-\ for\\:\\ 0\\.04377121653824892\ \(0\)\
\-\ interstitial\\:\\ 0\\.04363981640707997\ \(0\)\
\-\ african\\:\\ 0\\.04347907083029507\ \(0\)\
\-\ times\\:\\ 0\\.04332133002036525\ \(0\)\
\-\ spread\\:\\ 0\\.043243551703671834\ \(0\)\
\-\ mediastinum\\:\\ 0\\.04309011315619733\ \(0\)\
\-\ fungal\\:\\ 0\\.04309011315619733\ \(0\)\
\-\ tb\\:\\ 0\\.04286506281595987\ \(0\)\
\-\ versus\\:\\ 0\\.04257403785153703\ \(0\)\
\-\ end\\:\\ 0\\.04236217180443178\ \(0\)\
\-\ dyspnea\\:\\ 0\\.04236217180443178\ \(0\)\
\-\ current\\:\\ 0\\.04215549483880114\ \(0\)\
\-\ form\\:\\ 0\\.04208771224447666\ \(0\)\
\-\ pneumothorax\\:\\ 0\\.0419537588347409\ \(0\)\
\-\ main\\:\\ 0\\.0419537588347409\ \(0\)\
\-\ scans\\:\\ 0\\.04188757114153751\ \(0\)\
\-\ that\\:\\ 0\\.04178059489249546\ \(0\)\
\-\ regions\\:\\ 0\\.04131414314176097\ \(0\)\
\-\ must\\:\\ 0\\.04125276914307136\ \(0\)\
\-\ those\\:\\ 0\\.041191838281810556\ \(0\)\
\-\ ca\\:\\ 0\\.04107128069400746\ \(0\)\
\-\ disorder\\:\\ 0\\.04071960949212206\ \(0\)\
\-\ numerous\\:\\ 0\\.040662396475531125\ \(0\)\
\-\ so\\:\\ 0\\.04049304856607133\ \(0\)\
\-\ lobes\\:\\ 0\\.04016421913648403\ \(0\)\
\-\ resulting\\:\\ 0\\.0400573963477904\ \(0\)\
\-\ per\\:\\ 0\\.03995190887894976\ \(0\)\
\-\ 70\\:\\ 0\\.03974480921865485\ \(0\)\
\-\ complaints\\:\\ 0\\.03964313464386905\ \(0\)\
\-\ affected\\:\\ 0\\.03959275307557745\ \(0\)\
\-\ atypical\\:\\ 0\\.03949288341741138\ \(0\)\
\-\ parenchyma\\:\\ 0\\.03910482021441769\ \(0\)\
\-\ 27\\:\\ 0\\.03901052998628847\ \(0\)\
\-\ function\\:\\ 0\\.03896377702668569\ \(0\)\
\-\ etiology\\:\\ 0\\.03877931312212055\ \(0\)\
\-\ features\\:\\ 0\\.038733820356296474\ \(0\)\
\-\ involved\\:\\ 0\\.038598795273738995\ \(0\)\
\-\ oral\\:\\ 0\\.0385542627818831\ \(0\)\
\-\ taken\\:\\ 0\\.038465896659032835\ \(0\)\
\-\ 90\\:\\ 0\\.038465896659032835\ \(0\)\
\-\ around\\:\\ 0\\.03842205818318319\ \(0\)\
\-\ same\\:\\ 0\\.03807931513238802\ \(0\)\
\-\ upon\\:\\ 0\\.03787196102431983\ \(0\)\
\-\ 16\\:\\ 0\\.03751109849880128\ \(0\)\
\-\ symptomatic\\:\\ 0\\.037015671652789\ \(0\)\
\-\ currently\\:\\ 0\\.036978739919343716\ \(0\)\
\-\ worsening\\:\\ 0\\.03676048065993068\ \(0\)\
\-\ system\\:\\ 0\\.036724646688366155\ \(0\)\
\-\ are\\:\\ 0\\.03653273185682725\ \(0\)\
\-\ unknown\\:\\ 0\\.03647798105535592\ \(0\)\
\-\ at\\:\\ 0\\.03636503079403017\ \(0\)\
\-\ pleural\\:\\ 0\\.036238321081305785\ \(0\)\
\-\ malignancy\\:\\ 0\\.036038179978366634\ \(0\)\
\-\ result\\:\\ 0\\.036038179978366634\ \(0\)\
\-\ pattern\\:\\ 0\\.03593986172890487\ \(0\)\
\-\ cough\\:\\ 0\\.03593986172890487\ \(0\)\
\-\ effusion\\:\\ 0\\.03574659631371363\ \(0\)\
\-\ its\\:\\ 0\\.035620168666328604\ \(0\)\
\-\ lungs\\:\\ 0\\.03552657560765108\ \(0\)\
\-\ appears\\:\\ 0\\.03525186784876877\ \(0\)\
\-\ weakness\\:\\ 0\\.03513258829937843\ \(0\)\
\-\ involvement\\:\\ 0\\.03484156333495558\ \(0\)\
\-\ pt\\:\\ 0\\.034643657402900464\ \(0\)\
\-\ presence\\:\\ 0\\.034587954972122796\ \(0\)\
\-\ including\\:\\ 0\\.03445028654181517\ \(0\)\
\-\ middle\\:\\ 0\\.034423020322219694\ \(0\)\
\-\ risk\\:\\ 0\\.03439584191668801\ \(0\)\
\-\ otherwise\\:\\ 0\\.03431482797331316\ \(0\)\
\-\ 50\\:\\ 0\\.033618708425491965\ \(0\)\
\-\ being\\:\\ 0\\.03354479068904098\ \(0\)\
\-\ side\\:\\ 0\\.03325542905124682\ \(0\)\
\-\ 12\\:\\ 0\\.03290714492049795\ \(0\)\
\-\ masses\\:\\ 0\\.03277175879284133\ \(0\)\
\-\ thickening\\:\\ 0\\.03274940411056812\ \(0\)\
\-\ less\\:\\ 0\\.03274940411056812\ \(0\)\
\-\ areas\\:\\ 0\\.03268269318906537\ \(0\)\
\-\ fever\\:\\ 0\\.03263851043042502\ \(0\)\
\-\ recent\\:\\ 0\\.032594557791362375\ \(0\)\
\-\ followed\\:\\ 0\\.032507333370147266\ \(0\)\
\-\ bilaterally\\:\\ 0\\.03210490112514641\ \(0\)\
\-\ right\\:\\ 0\\.0319197994380436\ \(0\)\
\-\ should\\:\\ 0\\.03141035876942416\ \(0\)\
\-\ superior\\:\\ 0\\.0312968294209948\ \(0\)\
\-\ between\\:\\ 0\\.03127805546970703\ \(0\)\
\-\ known\\:\\ 0\\.03116628048961813\ \(0\)\
\-\ any\\:\\ 0\\.031110943323307955\ \(0\)\
\-\ approximately\\:\\ 0\\.030715859414731855\ \(0\)\
\-\ day\\:\\ 0\\.03066338947809004\ \(0\)\
\-\ days\\:\\ 0\\.030473743572979304\ \(0\)\
\-\ some\\:\\ 0\\.03028826604909599\ \(0\)\
\-\ primary\\:\\ 0\\.02959997541895464\ \(0\)\
\-\ pulmonary\\:\\ 0\\.029342626167895118\ \(0\)\
\-\ when\\:\\ 0\\.02907843071793018\ \(0\)\
\-\ weeks\\:\\ 0\\.028850338789040822\ \(0\)\
\-\ time\\:\\ 0\\.028532894304620565\ \(0\)\
\-\ performed\\:\\ 0\\.028478885239479834\ \(0\)\
\-\ therapy\\:\\ 0\\.027658682045363543\ \(0\)\
\-\ than\\:\\ 0\\.027288338802708086\ \(0\)\
\-\ patients\\:\\ 0\\.027080530795778813\ \(0\)\
\-\ prior\\:\\ 0\\.026933567216746696\ \(0\)\
\-\ both\\:\\ 0\\.026844383954766536\ \(0\)\
\-\ more\\:\\ 0\\.026433177316283953\ \(0\)\
\-\ symptoms\\:\\ 0\\.026338652384489812\ \(0\)\
\-\ follow\\:\\ 0\\.025950823885161043\ \(0\)\
\-\ bilateral\\:\\ 0\\.02587139847416684\ \(0\)\
\-\ chest\\:\\ 0\\.025409932028870413\ \(0\)\
\-\ most\\:\\ 0\\.025052725565467338\ \(0\)\
\-\ other\\:\\ 0\\.02499908838729197\ \(0\)\
\-\ were\\:\\ 0\\.024813998314919164\ \(0\)\
\-\ lower\\:\\ 0\\.02459881869101423\ \(0\)\
\-\ findings\\:\\ 0\\.023758273447772076\ \(0\)\
\-\ multiple\\:\\ 0\\.02354558095312559\ \(0\)\
\-\ female\\:\\ 0\\.023229039554759308\ \(0\)\
\-\ within\\:\\ 0\\.022171102010348023\ \(0\)\
\-\ which\\:\\ 0\\.021889048320012133\ \(0\)\
\-\ normal\\:\\ 0\\.01965462085484662\ \(0\)\
\-\ be\\:\\ 0\\.01952785910238285\ \(0\)\
\-\ history\\:\\ 0\\.018391688239392252\ \(0\)\
\-\ pain\\:\\ 0\\.01722572167748916\ \(0\)\
\-\ was\\:\\ 0\\.01677673879604218\ \(0\)\
\-\ left\\:\\ 0\\.016421087310419077\ \(0\)\
\-\ patient\\:\\ 0\\.015657032732037227\ \(0\)\
